

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-23. (Cancelled)

24. (currently amended) A nucleic acid according to claim ~~[[21]]~~ 99, wherein the zinc finger protein is a fusion protein comprising a regulatory domain.

25-85. (Cancelled)

86. (currently amended) A pharmaceutical composition for modulation of angiogenesis comprising

(a) a nucleic acid according to claim ~~[[21]]~~ 99 operably linked to a regulatory sequence, wherein the regulatory sequence allows for expression of the nucleic acid in a cell; and

(b) a pharmaceutically acceptable carrier or diluent.

87. (original) The pharmaceutical composition according to claim 86, wherein the nucleic acid is contained in an expression vector.

88. (original) The pharmaceutical composition according to claim 87, wherein the expression vector is a viral expression vector.

89. (original) The pharmaceutical composition according to claim 88, wherein the expression vector is selected from the group consisting of a retroviral expression vector, an adenoviral expression vector, and an AAV expression vector.

90-98. (Cancelled)